3 Results for "

NCI-H660

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "NCI-H660" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-144878
CAS No.: 2361742-30-3
Purity:  99.93%
Target:  

c-Myc

Research Areas:  

Cancer

VPC-70619 is a potent N-Myc inhibitor. VPC-70619 blocks the binding of the N-Myc-Max heterocomplex to the DNA E-box and exhibits potent inhibitory activity against N-Myc-dependent cell lines. VPC-70619 can partially reverse paclitaxel (HY-B0015) resistance in cells by reducing MYCN expression. VPC-70619 can be used for cancer research (e.g., neuroblastoma and thyroid cancer) .
loading...
    loading...
Cat. No.: HY-159072
CAS No.: 2575682-08-3
Purity:  96.22%
Research Areas:  

Cancer

Mal-Val-Ala-PAB-N(SO2Me)-Exatecan (Compound LE14) is a conjugate of an ADC toxin Exatecan (HY-13631) and a linker Mal-Val-Ala-PAB-N(SO2Me). Mal-Val-Ala-PAB-N(SO2Me)-Exatecan can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a delta-like ligand 3 (DLL3, KD=58.3 pM) targeting ADC, that exhibits antitumor efficacy against SCLC cancer .
loading...
    loading...
Cat. No.: HY-159072A
Mal-Val-Ala-PAB-N(SO2Me)-Exatecan TFA is a conjugate of an ADC toxin Exatecan (HY-13631) and a linker Mal-Val-Ala-PAB-N(SO2Me). Mal-Val-Ala-PAB-N(SO2Me)-Exatecan TFA can be used for synthesis of ADC FZ-AD005. FZ-AD005 is a delta-like ligand 3 (DLL3, KD=58.3 pM) targeting ADC, that exhibits antitumor efficacy against SCLC cancer .
loading...
    loading...